Modeling prion-like processing of tau protein in Alzheimer’s disease for pharmaceutical development

Manuscript Number: 

17-0727R1

Author(s): 
Charles R. Harrington, Björn O. Schelter, John M.D. Storey, Claude M. Wischik, Damon J. Wischik

Disclosures

Charles R. Harrington

  • Equity:
    I have stock options in TauRx Therapeutics
    Sponsors:
    I am Chief Scientific Officer for TauRx Therapeutics.
    Patents/Royalties
    I am named inventor on a number of patents relating to compounds and their uses in treatment of Alzheimer's disease and in inhibition of tau aggregation.

Björn O. Schelter

  • Consulting Fees:
    Paid consultant for TauRx Therapeutics.
    Grants
    • Agency: 
      GTD Dementia research project
      Dates: 
      01.09.2013 - 31.07.2018

John M.D. Storey

  • Equity:
    I have equity stake in the privately listed TauRx Therapeutics
    Sponsors:
    I serve as Head of Technical at TauRx Therapeutics
    Patents/Royalties
    I have patents (granted and pending) in the field of synthesis and use of compounds for the treatment of Alzheimer's disease and other related conditions.

Claude M. Wischik

  • Equity:
    I own stock in privately traded TauRx Therapeutics.
    Sponsors:
    I serve as Executive Chairman for TauRx Therapeutics
    Patents/Royalties
    I am named inventor on a number of patents relating to compounds and their uses in treatment of Alzheimer's disease and in inhibition of tau aggregation.

Damon J. Wischik

  • Patents/Royalties
    PCT international applications: WO08/155533, WO09/044127, WO09/060191, 2008.
    Grants
    • Agency: 
      Silicon Valley Community Foundation
      Dates: 
      2017-07-01 to 2018-07-01